In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biogen, Elan to co-develop and sell Antegren; deal terminated

Executive Summary

Elan and Biogen have formed an exclusive worldwide agreement to develop, manufacture, and sell Elan's Antegren (natalizumab), a humanized monoclonal antibody now in Phase II clinical trials to treat multiple sclerosis and Crohn's disease, a chronic inflammatory gastrointestinal disorder.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register